Status: Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Participants needed: 160
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eikon TherapeuticsUpdated: Apr 8, 2026Locations: 10
Eligibility criteria
is ≥ 18 years of age at the time of signing the informed consent. [+6]
has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer the... [+10]